--- title: "Harrow (HROW) Could Be 38% Undervalued Following BYOOVIZ Launch" type: "News" locale: "en" url: "https://longbridge.com/en/news/291678364.md" description: "Harrow (HROW) is viewed as potentially 38% undervalued following the US launch of BYOOVIZ, a Lucentis biosimilar with FDA interchangeability status. Trading at $42.74, the stock sits below the analyst-derived fair value of $68.38, driven by expected revenue growth from specialty ophthalmic drugs like VEVYE and IHEEZO amid aging populations. However, risks include dependence on key products and potential pricing pressures." datetime: "2026-07-03T15:57:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291678364.md) - [en](https://longbridge.com/en/news/291678364.md) - [zh-HK](https://longbridge.com/zh-HK/news/291678364.md) generator: "portal-rs" --- # Harrow (HROW) Could Be 38% Undervalued Following BYOOVIZ Launch ## Why Harrow stock is in focus after the BYOOVIZ launch Harrow (HROW) is back on investors’ radar after launching BYOOVIZ in the US, a Lucentis biosimilar that carries FDA interchangeability status for several retinal conditions tied to anti VEGF treatment. See our latest analysis for Harrow. Harrow’s official BYOOVIZ launch comes after a sharp 28.27% 1 month share price gain and a 21.04% 3 month share price return, while the year to date share price is still down 14.37%. Over the longer term, total shareholder returns of 34.61% over 1 year and more than 4x over 5 years show momentum has generally been building. If the BYOOVIZ news has you looking more broadly at eyecare and treatment technologies, it could be a useful moment to scan other opportunities in healthcare focused AI using the 40 healthcare AI stocks With Harrow shares up sharply in the past month, trading at $42.74 and sitting at a sizable discount to the average analyst target of $67.75, the key question is whether there is still a buying opportunity or whether markets are already pricing in future growth. ## Most Popular Narrative: 38% Undervalued Harrow’s most followed valuation narrative pegs fair value at $68.38, well above the recent $42.74 close, putting a spotlight on what is driving that gap. > *The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool supporting sustainable long-term revenue growth.* *Read the complete narrative.* Curious what sits behind that fair value for Harrow? The narrative leans heavily on brisk top line expansion, rising margins and a future earnings profile that contrasts sharply with today’s losses. **Result: Fair Value of $68.38 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the Harrow narrative could be knocked off course if dependence on a handful of flagship drugs bites, or if pricing and reimbursement pressures hit harder than expected. Find out about the key risks to this Harrow narrative. ## Next Steps If this Harrow story sounds compelling, now is the time to check the numbers yourself and evaluate the potential impact on your portfolio using the 2 key rewards ## Looking for more investment ideas beyond Harrow? If Harrow has sharpened your interest in healthcare and beyond, do not stop here. Broaden your watchlist now so you do not miss the next opportunity. - Target higher potential by scanning focused opportunities using the 43 high quality undervalued stocks that could complement your Harrow thesis. - Strengthen your downside protection by reviewing companies screened in the 75 resilient stocks with low risk scores with resilience front and center. - Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before these ideas move firmly into the spotlight. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md) - [HROW.US](https://longbridge.com/en/quote/HROW.US.md) - [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md) ## Related News & Research - [Harrow (HROW) Dropped, So What Is Behind The Latest Attention?](https://longbridge.com/en/news/297230624.md) - [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md) - [Impiricus Launches QPharma® Integration to Power Real-Time Compliant HCP Sampling](https://longbridge.com/en/news/296957896.md) - [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md) - [Bausch + Lomb Advancing Two First-In-Class Eye Health Therapies Based On Trial Results](https://longbridge.com/en/news/296827543.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**